Healthcare - Biotechnology - NASDAQ - US
$ 1.83
-3.17 %
$ 91.1 M
Market Cap
-0.59
P/E
CASH FLOW STATEMENT
-86.8 M
OPERATING CASH FLOW
-94.6 M
INVESTING CASH FLOW
119 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
HilleVax, Inc.
| Net Income | -124 M |
| Depreciation & Amortization | 2.16 M |
| Capital Expenditures | -10.7 M |
| Stock-Based Compensation | 13.6 M |
| Change in Working Capital | 22.8 M |
| Others | 6.63 M |
| Free Cash Flow | -97.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (123.6) | (159.8) | (102.4) | (2.1) | (0.7) |
| Depreciation & Amortization | 2.2 | 1 K | 3 K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 25.9 | 0 | 0 |
| Stock Based Compensation | 13.6 | 3.0 | 67 K | 0 | 0 |
| Other Operating Activities | (1.8) | 100.2 | 57.9 | 0.8 | 31 K |
| Change in Working Capital | 22.8 | (5.4) | 11.3 | 52 K | 0.2 |
| Cash From Operations | (86.8) | (62.0) | (7.3) | (1.3) | (0.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (10.7) | (6.5) | (2.8) | 0 | 0 |
| Other Items | (83.9) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (94.6) | (6.5) | (2.8) | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 9.8 | 14.7 | 135.0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (19.7) | (0.8) | 1.3 | 0.9 |
| Cash From Financing Activities | 118.7 | 225.0 | 134.2 | 1.3 | 0.9 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (62.7) | 156.5 | 124.1 | 54 K | 0.4 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (97.5) | (68.5) | (10.1) | (1.3) | (0.5) |